Sanofi API Unit Expects $1bn Sales By 2022
New API Company Will Cut European Reliance On Asian Raw Materials
Sanofi has announced plans to create the world’s second-largest API manufacturer to help ease European drugmakers’ dependence on supplies of raw materials from China and India.
You may also be interested in...
Weaknesses in the global pharmaceutical supply chain, exposed and exacerbated by the coronavirus pandemic, have led major markets to pursue localization policies aimed at bolstering domestic production capacity. But any significant transformation promises to take many years.
Sanofi has unveiled further details of its European API company, which will be called Euroapi and will be led by Karl Rotthier as CEO.
India has published a list of APIs and formulations for which exports will be restricted, with immediate effect. The move comes against the backdrop of growing concerns over the off-patent industry’s supply chain given the ongoing pressures caused by the coronavirus outbreak.